RT Journal Article
SR Electronic
T1 Mathematical estimation of COVID-19 prevalence in Latin America
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.09.20126326
DO 10.1101/2020.06.09.20126326
A1 Matabuena, Marcos
A1 Rodríguez-Mier, Pablo
A1 Meijide-García, Carlos
A1 Leborán, Víctor
A1 Gude, Francisco
YR 2020
UL http://medrxiv.org/content/early/2020/06/11/2020.06.09.20126326.abstract
AB After the rapid spread with severe consequences in Europe and China, the SARS-CoV-2 virus is now manifesting itself in more vulnerable countries, including those in Latin America. In order to guide political decision-making via epidemiological criteria, it is crucial to assess the real impact of the epidemic. However, the use of large-scale population testing is unrealistic or not feasible in some countries. Based on a newly developed mathematical model, we estimated the seroprevalence of SARS-CoV-2 in Latin American countries. The results show that the virus spreads unevenly across countries. For example, Ecuador and Brazil are the most affected countries, with approximately 3% of the infected population. Currently, the number of new infections is increasing in all countries examined, with the exception of some Caribbean countries as Cuba. Moreover, in these countries, the peak of newly infected patients has not yet been reached.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work has received financial support from Carlos III Health Institute, Grant/Award Number: COV20/00404, Ministry of Economy and Competitiveness (SPAIN) and the European Regional Development Fund (FEDER); and the Axencia Galega de Innovacion, Consellerı́a de Economia, Emprego e Industria, Xunta de Galicia, Spain, Grant/Award Number: GPC IN607B 2018/01.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethics committee is necessary in this researchAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOfficial data are obtained through John Hopkins repository (https://github.com/CSSEGISandData/COVID-19/tree/master/csse_covid_19_data/csse_covid_19_time_series).